Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Moleculin Biotech is a late-stage pharmaceutical company focused on developing innovative cancer therapies. Its lead drug, Annamycin, is a non-cardiotoxic anthracycline targeting relapsed/refractory AML and lung metastases, with potential applications in hard-to-treat cancers. The company advances its portfolio through clinical trials, leveraging proprietary lipid technology and collaborations with academic institutions to address unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.